Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint Inhibitors
JACC: Advances · 2024-12 · 3 (12) · 101375
DOI: 10.1016/j.jacadv.2024.101375 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Advances, 2024-12. Verfasst von Pieter F van den Berg und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nederlandse Hartstichting, European Research Council, Fondation Leducq.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of cancer. However, immune-related adverse events are prevalent in patients receiving ICI therapy. A serious immune-related adverse event is ICI-myocarditis, which is complex to diagnose given that the significance of early symptoms and biomarker trajectories, such as high-sensitivity troponin T (hs-TnT) are unclear.
Objectives
The purpose of the study was to evaluate kinetics of hs-TnT in cancer patients receiving ICI and to identify patients at risk of developing ICI-myocarditis.
Methods
This prospective, observational, single-center study included 164 patients receiving ICI therapy. Patients' history, demographics, and clinical characteristics, as well as survival statistics, were collected from electronic patient records and used to analyze associations between elevated hs-TnT (≥14 ng/L) and a significant rise in hs-TnT (100% rise from baseline, with an absolute value ≥2x upper limit of normal (ie, ≥28 ng/L) with ICI-myocarditis.
Results
We included 164 patients with a mean follow-up time of 1.60 ± 0.91 years. Melanoma was the most common type of cancer in the patient population, and most patients received treatment with programmed cell death protein 1 (PD-1). Twenty-six patients (16%) exhibited significant hs-TnT elevations, while 8 patients (5%) developed ICI-myocarditis. In 18 of 26 (69%) patients, ICI-myocarditis could not be diagnosed with certainty, while 10 of 26 (38%) patients had no other signs of symptoms of cardiac damage. All 8 myocarditis cases were preceded by significantly higher hs-TnT elevations than asymptomatic patients. Despite a high ICI-myocarditis incidence in our study population, cardiac mortality remained low (4%).
Conclusions
Significant hs-TnT elevations occur more often than previously reported, are often asymptomatic, and do not always lead to myocarditis diagnosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands.
- Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands.
- Erasmus Medical Center, Cardiovascular Institute, Thorax Center, Department of Cardiology, Rotterdam, the Netherlands.
Förderung
- Nederlandse Hartstichting
- European Research Council
- Fondation Leducq
- Rijksuniversiteit Groningen
Zitieren
APA
van den Berg, P. F., Bracun, V., Noordman, M., van der Meer, P., Shi, C., Oosting, S. F., Aboumsallem, J. P., de Wit, S., Meijers, W. C., Jalving, M., van Kruchten, M., & de Boer, R. A. (2024). Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint Inhibitors. JACC: Advances, 3(12), 101375. https://doi.org/10.1016/j.jacadv.2024.101375
Vancouver
van den Berg PF, Bracun V, Noordman M, van der Meer P, Shi C, Oosting SF, et al. Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint Inhibitors. JACC: Advances. 2024;3(12):101375. doi:10.1016/j.jacadv.2024.101375
BibTeX
@article{vandenBerg2024,
author = {van den Berg, Pieter F and Bracun, Valentina and Noordman, Michel and van der Meer, Peter and Shi, Canxia and Oosting, Sjoukje F and Aboumsallem, Joseph Pierre and de Wit, Sanne and Meijers, Wouter C and Jalving, Mathilde and van Kruchten, Michel and de Boer, Rudolf A},
title = {Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint Inhibitors},
journal = {JACC: Advances},
year = {2024},
volume = {3},
number = {12},
pages = {101375},
doi = {10.1016/j.jacadv.2024.101375}
}
EUVIMED